Emergency management in the allergological practice: Prevention of iatrogenic anaphylactic reactions;Prävention iatrogen bedingter anaphylaktischer reaktionen

Allergologie

Volumn 26, Issue 2, 2003, Pages 78-83

  Boehncke, W H ^a   Ahlbach, S ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Anaphylaxis; Risk factor; Skin test; Specific immunotherapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ALLERGIC ASTHMA; ALLERGIC REACTION; ANAPHYLAXIS; EMERGENCY TREATMENT; EXERCISE; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; INFECTION; REVIEW; RISK FACTOR; SKIN TEST; TREATMENT PLANNING;

EID: 0037327197     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Anderson J.A. et al.: Position statement: the waiting period after allergen skin testing and immunotherapy. J. Allergy Clin. Immunol. 85, 526-527 (1990).
2. Boehncke W.-H.: Epidemiologie der atopischen Dermatitis. In: Zollner T.M., W.-H. Boehncke, R. Kaufmann: Atopische Dermatitis. Blackwell, Berlin 2002, 5-18.
3. Bousquet J., R.F. Lockey, H.J. Malling: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102, 558-562 (1998).
4. Dogliotti M.: An instance of fatal reaction to the penicillin scratch test. Dermatologica 136, 489 (1968).
5. Fricker M. et al.: Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J. Allergy Clin. Immunol. 101, 11-15 (1997).
6. Hejjaouri A. et al.: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J. Allergy Clin. Immunol. 85, 473-479 (1990).
7. Hunt K.J. et al.: A controlled trial of immunotherapy in insect hypersensitivity. N. Engl. J. Med. 299, 157-161 (1978).
8. Kleine-Tebbe J. et al.: Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen. Allergo J. 9, 317-324 (2000).
9. Lamson R. W.: Sudden death associated with injection of foreign substances. JAMA 82, 1090 (1924).
10. Lockey R.F. et al.: Fatalities from immunotherapy (IT) and skin testing (ST). J. Allergy Clin. Immunol. 79, 660-677 (1987).
11. Lockey R.F. et al.: Systemic reaction and fatalities associated with allergen immunotherapy. Ann. Allergy Asthma Immunol. 87 (Suppl.), 47-55 (2001).
12. Lockey R.F. et al.: The hymenoptera venom study II: skin test results and safety of venom skin testing. J. Allergy Clin. Immunol. 84, 967-974 (1989).
13. Lockey R.F. et al.: The hymenoptera venom study III: safety of venom immunotherapy. J. Allergy Clin. Immunol. 86, 775-780 (1990).
14. Norman PS.:. Fatal misadventures. Clin. Immunol. 79, 572-573 (1987).
15. Pumphrey R.S.H.: Lessons for management of anaphylaxis from a study of fatal reactions. Clin. Exp. Allergy 30, 1144-1150 (2000).
16. Reid M.J. et al.: Survey of fatalities from skin testing and immunotherapy 1985-1989. J. Allergy Clin. Immunol. 92, 6-15 (1993).
17. Ring J. et al.: Weißbuch Allergie in Deutschland 2000. Urban und Vogel, München 2000.
18. Rueff F. et al.: Diagnose und Therapie der Bienen- und Wespengiftallergie. Allergo J. 9, 458-472 (2000).
19. Schwartz H.J., D.B.K. Golden, R.F. Lockey: Venom immunotherapy in the hymenoptera-allergic pregnant patient. J. Allergy Clin. Immunol. 85, 709-712 (1990).
20. Committee on Safety of Medicines (CSM): Update: desensitization vaccines. Br. Med. J. 293, 948 (1986).